Key result
Cochrane review protocol evaluates treat-to-target versus no-target lipid strategies for cardiovascular disease prevention.
Why the study?
The benefits and harms of treat-to-target versus no-target lipid-lowering strategies for primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia are unclear.
Does a treat-to-target strategy for lipid-lowering therapy improve outcomes compared to a no-target strategy in adults with dyslipidaemia?
Does a treat-to-target strategy for lipid-lowering therapy improve outcomes compared to a no-target strategy in adults with dyslipidaemia?
This is a protocol for a Cochrane review evaluating treat-to-target versus no-target strategies for lipid-lowering therapy in adults with dyslipidaemia.
OBJECTIVES: This is a protocol for a Cochrane review (intervention). The objectives are as follows: To evaluate the benefits and harms of a treat-to-target (goal-directed) strategy versus a no-target strategy for lipid-lowering therapy in the primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia.
No takes yet. Share an insight, caveat, or question.
Shokraee et al. (2026) studied this question. Treat-to-target lipid-lowering strategies are being evaluated against no-target strategies for cardiovascular disease prevention in adults with dyslipidemia in a Cochrane review protocol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: